SignPath Pharma Announces Orphan Drug Designation and Fast Track Submission for LipoCurc™ in Glioblastoma
SignPath Pharma advances LipoCurc™ GBM program with FDA Orphan Drug Designation and submission of Fast Track and CNPV requests SANDY, UT, UNITED STATES, December 16, 2025 /EINPresswire.com/ -- SignPath Pharma, Inc., a clinical-stage biotechnology …